文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

ResistancePlus GC (beta) 检测法评估:直接检测淋球菌对环丙沙星敏感性或耐药性的商业诊断测试

Evaluation of the ResistancePlus GC (beta) assay: a commercial diagnostic test for the direct detection of ciprofloxacin susceptibility or resistance in Neisseria gonorrhoeae.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

该研究评估了 ResistancePlus GC (beta) 检测法在临床标本和分离株中同时检测淋病奈瑟菌及其 gyrA S91 耐药/敏感标志物的性能。结果显示,该检测法对淋球菌检测灵敏度达100%(分离株)和>96%(临床标本),对 gyrA S91 突变检测在临床分离株中与基因型相比灵敏度和特异度均为100%,与表型相比灵敏度和特异度均>99%/>97%。结论认为该检测法适用于临床样本直接检测,可指导个体化治疗并加强耐药监测。

要点

  • ResistancePlus GC (beta) 可同时检测淋球菌和 gyrA S91 耐药/敏感标志物。
  • 临床分离株中淋球菌检测灵敏度100%,临床标本中>96%。
  • gyrA S91 突变检测与基因型一致(100%),与表型相比>99%/>97%。

核心结论

  • ResistancePlus GC (beta) 检测法适用于直接从临床样本中检测淋病奈瑟菌及与环丙沙星耐药/敏感相关的 gyrA 标志物。
  • 该检测法可用于淋病感染的个体化治疗,并增强现有抗菌药物耐药监测方法。

研究设计与样本

  • 评估 ResistancePlus GC (beta) 检测法性能,样本包括淋球菌分离株(n=822)、非淋球菌分离株(n=110)、淋球菌阳性临床标本(n=402)和淋球菌阴性标本(n=290)。
  • 结果与既往检测数据比较,包括 S91 基因分型和表型耐药谱。

主要发现

  • 在临床分离株中,检测淋球菌的总体灵敏度为100%。
  • 在临床分离株中,检测 gyrA S91 突变与基因型相比灵敏度和特异度均为100%,与表型相比灵敏度>99%、特异度>97%。
  • 在阳性临床标本中,检测淋球菌灵敏度>96%,检测 gyrA S91 突变灵敏度和特异度均为100%。
  • 检测淋球菌对非淋球菌分离株的特异度>99%,对阴性临床标本的特异度为100%。

临床怎么用

  • 可考虑将 ResistancePlus GC (beta) 检测法用于淋病感染的个体化治疗决策。
  • 该检测法可增强当前抗菌药物耐药监测方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the performance of the ResistancePlus GC (beta) assay for the simultaneous detection of Neisseria gonorrhoeae and gyrA S91 markers of resistance (S91F) and susceptibility (WT) to ciprofloxacin, from both clinical specimens and isolates. METHODS: Performance was assessed on several sample banks, including N. gonorrhoeae isolates (n = 822), non-gonococcal isolates (n = 110), N. gonorrhoeae-positive clinical specimens (n = 402) and N. gonorrhoeae-negative specimens (n = 290). Results were compared with previous testing data, including S91 genotyping and phenotypic resistance profiles. RESULTS: Overall, the assay demonstrated 100% sensitivity for N. gonorrhoeae detection in clinical isolates. For gyrA S91 mutation detection in clinical isolates, the assay showed 100% sensitivity/specificity compared with the genotype, and >99%/>97% sensitivity/specificity when compared with phenotype. For positive clinical specimens, the assay demonstrated >96% sensitivity for N. gonorrhoeae detection and 100% sensitivity/specificity for gyrA S91 mutation detection. The assay demonstrated >99% specificity for N. gonorrhoeae detection against non-gonococcal isolates and 100% specificity for negative clinical specimens. CONCLUSIONS: The ResistancePlus GC (beta) assay is suitable for the detection of N. gonorrhoeae and gyrA markers associated with resistance/susceptibility to ciprofloxacin directly in clinical samples. This assay could be implemented for the individualized treatment of gonorrhoea infections as well as to enhance current antimicrobial resistance surveillance methods.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ebeyan S, Windsor M, Bordin A, et al. Evaluation of the ResistancePlus GC (beta) assay: a commercial diagnostic test for the direct detection of ciprofloxacin susceptibility or resistance in Neisseria gonorrhoeae. J Antimicrob Chemother. 2019. PMID: 30897201. doi:10.1093/jac/dkz108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。